A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy

Norishige Yoshikawa, Hiroshi Ito, Tadasu Sakai, Yasuo Takekoshi, Masataka Honda, Midori Awazu, Katsumi Ito, Kikuo Iitaka, Yasushi Koitabashi, Kanji Yamaoka, Kimiko Nakagawa, Hajime Nakamura, Souichirou Matsuyama, Yoshiki Seino, Nobuaki Takeda, Shinzaburou Hattori, Makoto Ninomiya

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

The most appropriate treatment for patients with IgA nephropathy is controversial. Treatment with prednisolone, azathioprine, heparin-warfarin, and dipyridamole early in the course of disease may prevent immunologic renal injury in children with severe IgA nephropathy. To determine whether similar results can be obtained with a combination of just heparin-warfarin and dipyridamole, the effects of such treatment were compared to those of treatment with prednisolone, azathioprine, heparin-warfarin, and dipyridamole in 78 children with newly diagnosed IgA nephropathy showing diffuse mesangial proliferation. The patients were randomly assigned to receive either prednisolone, azathioprine, heparin-warfarin, and dipyridamole for 2 yr (group 1) or heparin-warfarin and dipyridamole for 2 yr (group 2). All of the 40 patients in group 1 and 34 of the 38 patients in group 2 completed the trial. The mean urinary protein excretion fell in group 1 patients (P ≤ 0.0001), but remained unchanged in group 2 patients. The mean serum IgA concentration was reduced in group I patients (P = 0.0002), but was unchanged in group 2 patients. BP and creatinine clearance were normal at the end of the trial in all but one group 2 patient, who developed chronic renal insufficiency. The percentage of glomeruli showing sclerosis was unchanged in group 1 patients, but increased in group 2 patients (P = 0.006). The intensity of mesangial IgA deposits decreased in group 1 patients (P = 0.02), but remained unchanged in group 2 patients. In conclusion, the present study shows that treatment of children with severe IgA nephropathy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for 2 yr early in the course of disease reduces immunologic renal injury and prevents increase of sclerosed glomeruli.

Original languageEnglish
Pages (from-to)101-109
Number of pages9
JournalJournal of the American Society of Nephrology
Volume10
Issue number1
Publication statusPublished - 1999 Jan
Externally publishedYes

Fingerprint

Immunoglobulin A
Dipyridamole
Warfarin
Heparin
Azathioprine
Prednisolone
Therapeutics
Kidney
Immune System Diseases
Wounds and Injuries
Sclerosis
Chronic Renal Insufficiency
Creatinine

ASJC Scopus subject areas

  • Nephrology

Cite this

Yoshikawa, N., Ito, H., Sakai, T., Takekoshi, Y., Honda, M., Awazu, M., ... Ninomiya, M. (1999). A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. Journal of the American Society of Nephrology, 10(1), 101-109.

A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. / Yoshikawa, Norishige; Ito, Hiroshi; Sakai, Tadasu; Takekoshi, Yasuo; Honda, Masataka; Awazu, Midori; Ito, Katsumi; Iitaka, Kikuo; Koitabashi, Yasushi; Yamaoka, Kanji; Nakagawa, Kimiko; Nakamura, Hajime; Matsuyama, Souichirou; Seino, Yoshiki; Takeda, Nobuaki; Hattori, Shinzaburou; Ninomiya, Makoto.

In: Journal of the American Society of Nephrology, Vol. 10, No. 1, 01.1999, p. 101-109.

Research output: Contribution to journalArticle

Yoshikawa, N, Ito, H, Sakai, T, Takekoshi, Y, Honda, M, Awazu, M, Ito, K, Iitaka, K, Koitabashi, Y, Yamaoka, K, Nakagawa, K, Nakamura, H, Matsuyama, S, Seino, Y, Takeda, N, Hattori, S & Ninomiya, M 1999, 'A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy', Journal of the American Society of Nephrology, vol. 10, no. 1, pp. 101-109.
Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. Journal of the American Society of Nephrology. 1999 Jan;10(1):101-109.
Yoshikawa, Norishige ; Ito, Hiroshi ; Sakai, Tadasu ; Takekoshi, Yasuo ; Honda, Masataka ; Awazu, Midori ; Ito, Katsumi ; Iitaka, Kikuo ; Koitabashi, Yasushi ; Yamaoka, Kanji ; Nakagawa, Kimiko ; Nakamura, Hajime ; Matsuyama, Souichirou ; Seino, Yoshiki ; Takeda, Nobuaki ; Hattori, Shinzaburou ; Ninomiya, Makoto. / A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. In: Journal of the American Society of Nephrology. 1999 ; Vol. 10, No. 1. pp. 101-109.
@article{bc4b661ab550488695bec813d9bda1a8,
title = "A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy",
abstract = "The most appropriate treatment for patients with IgA nephropathy is controversial. Treatment with prednisolone, azathioprine, heparin-warfarin, and dipyridamole early in the course of disease may prevent immunologic renal injury in children with severe IgA nephropathy. To determine whether similar results can be obtained with a combination of just heparin-warfarin and dipyridamole, the effects of such treatment were compared to those of treatment with prednisolone, azathioprine, heparin-warfarin, and dipyridamole in 78 children with newly diagnosed IgA nephropathy showing diffuse mesangial proliferation. The patients were randomly assigned to receive either prednisolone, azathioprine, heparin-warfarin, and dipyridamole for 2 yr (group 1) or heparin-warfarin and dipyridamole for 2 yr (group 2). All of the 40 patients in group 1 and 34 of the 38 patients in group 2 completed the trial. The mean urinary protein excretion fell in group 1 patients (P ≤ 0.0001), but remained unchanged in group 2 patients. The mean serum IgA concentration was reduced in group I patients (P = 0.0002), but was unchanged in group 2 patients. BP and creatinine clearance were normal at the end of the trial in all but one group 2 patient, who developed chronic renal insufficiency. The percentage of glomeruli showing sclerosis was unchanged in group 1 patients, but increased in group 2 patients (P = 0.006). The intensity of mesangial IgA deposits decreased in group 1 patients (P = 0.02), but remained unchanged in group 2 patients. In conclusion, the present study shows that treatment of children with severe IgA nephropathy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for 2 yr early in the course of disease reduces immunologic renal injury and prevents increase of sclerosed glomeruli.",
author = "Norishige Yoshikawa and Hiroshi Ito and Tadasu Sakai and Yasuo Takekoshi and Masataka Honda and Midori Awazu and Katsumi Ito and Kikuo Iitaka and Yasushi Koitabashi and Kanji Yamaoka and Kimiko Nakagawa and Hajime Nakamura and Souichirou Matsuyama and Yoshiki Seino and Nobuaki Takeda and Shinzaburou Hattori and Makoto Ninomiya",
year = "1999",
month = "1",
language = "English",
volume = "10",
pages = "101--109",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "1",

}

TY - JOUR

T1 - A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy

AU - Yoshikawa, Norishige

AU - Ito, Hiroshi

AU - Sakai, Tadasu

AU - Takekoshi, Yasuo

AU - Honda, Masataka

AU - Awazu, Midori

AU - Ito, Katsumi

AU - Iitaka, Kikuo

AU - Koitabashi, Yasushi

AU - Yamaoka, Kanji

AU - Nakagawa, Kimiko

AU - Nakamura, Hajime

AU - Matsuyama, Souichirou

AU - Seino, Yoshiki

AU - Takeda, Nobuaki

AU - Hattori, Shinzaburou

AU - Ninomiya, Makoto

PY - 1999/1

Y1 - 1999/1

N2 - The most appropriate treatment for patients with IgA nephropathy is controversial. Treatment with prednisolone, azathioprine, heparin-warfarin, and dipyridamole early in the course of disease may prevent immunologic renal injury in children with severe IgA nephropathy. To determine whether similar results can be obtained with a combination of just heparin-warfarin and dipyridamole, the effects of such treatment were compared to those of treatment with prednisolone, azathioprine, heparin-warfarin, and dipyridamole in 78 children with newly diagnosed IgA nephropathy showing diffuse mesangial proliferation. The patients were randomly assigned to receive either prednisolone, azathioprine, heparin-warfarin, and dipyridamole for 2 yr (group 1) or heparin-warfarin and dipyridamole for 2 yr (group 2). All of the 40 patients in group 1 and 34 of the 38 patients in group 2 completed the trial. The mean urinary protein excretion fell in group 1 patients (P ≤ 0.0001), but remained unchanged in group 2 patients. The mean serum IgA concentration was reduced in group I patients (P = 0.0002), but was unchanged in group 2 patients. BP and creatinine clearance were normal at the end of the trial in all but one group 2 patient, who developed chronic renal insufficiency. The percentage of glomeruli showing sclerosis was unchanged in group 1 patients, but increased in group 2 patients (P = 0.006). The intensity of mesangial IgA deposits decreased in group 1 patients (P = 0.02), but remained unchanged in group 2 patients. In conclusion, the present study shows that treatment of children with severe IgA nephropathy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for 2 yr early in the course of disease reduces immunologic renal injury and prevents increase of sclerosed glomeruli.

AB - The most appropriate treatment for patients with IgA nephropathy is controversial. Treatment with prednisolone, azathioprine, heparin-warfarin, and dipyridamole early in the course of disease may prevent immunologic renal injury in children with severe IgA nephropathy. To determine whether similar results can be obtained with a combination of just heparin-warfarin and dipyridamole, the effects of such treatment were compared to those of treatment with prednisolone, azathioprine, heparin-warfarin, and dipyridamole in 78 children with newly diagnosed IgA nephropathy showing diffuse mesangial proliferation. The patients were randomly assigned to receive either prednisolone, azathioprine, heparin-warfarin, and dipyridamole for 2 yr (group 1) or heparin-warfarin and dipyridamole for 2 yr (group 2). All of the 40 patients in group 1 and 34 of the 38 patients in group 2 completed the trial. The mean urinary protein excretion fell in group 1 patients (P ≤ 0.0001), but remained unchanged in group 2 patients. The mean serum IgA concentration was reduced in group I patients (P = 0.0002), but was unchanged in group 2 patients. BP and creatinine clearance were normal at the end of the trial in all but one group 2 patient, who developed chronic renal insufficiency. The percentage of glomeruli showing sclerosis was unchanged in group 1 patients, but increased in group 2 patients (P = 0.006). The intensity of mesangial IgA deposits decreased in group 1 patients (P = 0.02), but remained unchanged in group 2 patients. In conclusion, the present study shows that treatment of children with severe IgA nephropathy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for 2 yr early in the course of disease reduces immunologic renal injury and prevents increase of sclerosed glomeruli.

UR - http://www.scopus.com/inward/record.url?scp=0032946084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032946084&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 101

EP - 109

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 1

ER -